Can Metoprolol Be Given Through RT in Ventilated ADHF Patients?
Yes, metoprolol can be administered through a nasogastric or orogastric tube in ventilated patients with acute decompensated heart failure, and beta-blockers should generally be continued during ADHF hospitalization unless hemodynamic instability is present.
Key Recommendation
Beta-blockers should be continued or dose-reduced (not discontinued) in ADHF patients, including those who are mechanically ventilated, unless there is cardiogenic shock or severe hemodynamic instability 1, 2. The FDA label does not specifically contraindicate enteral tube administration of metoprolol succinate extended-release tablets 3.
Clinical Approach
When to Continue Beta-Blockers via RT:
- Hemodynamically stable patients: Continue home dose or reduce by 50% if mild hypotension
- NYHA Class II-III heart failure: Maintain therapy to prevent rebound sympathetic activation
- Absence of cardiogenic shock: Beta-blockers are contraindicated only in decompensated cardiac failure with shock 3
When to Hold or Reduce Dose:
- Severe bradycardia (<50 bpm)
- Second or third-degree heart block 3
- Cardiogenic shock with hypotension requiring vasopressors 3
- Symptomatic hypotension (SBP <90 mmHg with end-organ hypoperfusion)
Evidence Supporting Continuation
Recent meta-analysis data suggest that discontinuation of beta-blockers during ADHF may be associated with increased short-term mortality (pooled HR: 2.30; 95% CI: 1.23-4.29) 4. While this evidence is of low certainty due to confounding, it supports the practice of continuation when feasible.
Multiple sources emphasize that pre-existing beta-blocker therapy should be continued if there is no hemodynamic instability 2. The rationale is that abrupt discontinuation can trigger rebound sympathetic activation, potentially worsening outcomes.
Practical Administration via RT
Tube Administration Considerations:
- Crush immediate-release metoprolol tartrate tablets and administer via tube with water flush
- Do NOT crush extended-release formulations (metoprolol succinate ER) - these should be avoided in tube-fed patients or switched to immediate-release formulation
- Flush tube with 30 mL water before and after administration
- Administer with or immediately following tube feeds when possible 3
Dosing in ADHF:
- If continuing home dose: Start with 50% dose reduction if any concern for hypotension
- Monitor heart rate and blood pressure closely for 2-4 hours post-administration
- Target heart rate 60-80 bpm in ventilated patients
- Typical doses: 25-50 mg twice daily (immediate-release) or 50-100 mg daily (if using ER formulation whole via large-bore tube)
Critical Pitfalls to Avoid
- Do not abruptly discontinue beta-blockers without clear contraindication - this may worsen outcomes 4
- Do not use in cardiogenic shock requiring inotropes/vasopressors 3
- Do not crush extended-release formulations - switch to immediate-release if crushing needed
- Monitor for symptomatic bradycardia - reduce dose rather than discontinue if this occurs 3
- Ensure adequate decongestion first - optimize diuretics and vasodilators before focusing on beta-blocker dosing 5
Monitoring Parameters
- Heart rate: Target 60-80 bpm
- Blood pressure: Maintain SBP >90 mmHg
- Signs of hypoperfusion: Mental status, urine output, lactate
- Congestion status: Daily weights, lung exam, jugular venous pressure
The primary focus in ADHF should remain on achieving complete decongestion with diuretics and vasodilators 5, while maintaining beta-blocker therapy when hemodynamically tolerated to prevent withdrawal effects and maintain long-term mortality benefits established in chronic heart failure 6.